RMTI Rockwell Medical
Methods of Reducing Doses of Erythropoietin Stimulating Agents in Hyporesponsive Patients
18 Nov 20
The invention provides for methods of treating a dialysis patient that is hyporesponsive to erythropoietin stimulating agents (ESA) comprising administering soluble ferric triphosphate (SFP) composition and administering a dose of ESA that is significantly reduced compared to the dose of ESA required by a dialysis patient that is hyporesponsive to ESA that has not received SFP.
Ajay Gupta, Raymond Pratt, Vivian H. Lin, Carrie Guss
Filed: 3 Aug 20
Patents are sorted by USPTO publication date, most recent first